ArticlePeerJ2019

Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study.

Yu-Fen Tsai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.